Europe's STOXX 600 ended the day slightly up, driven by a surge in Novo Nordisk shares that helped the healthcare sector. Low trading volumes characterized the day due to holiday anticipation, while ...

Europe's STOXX 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk shares boosted ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

European markets edge higher as Novo Nordisk rebounds, with gains led by healthcare and tech sectors despite lingering ...

Analysts at Intron Health, led by Naresh Chouhan, suggested that Friday's market reaction was excessively severe.

BMO Capital lowered the firm’s price target on Novo Nordisk (NVO) to $105 from $156 but keeps an Outperform rating on the shares. The ...

Asian and European stock markets were largely getting off to a good start to a holiday-shortened Christmas week. Bargain hunting was in evidence as Novo Nordisk rose following a sharp drop for the ...

Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...

Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

However, Novo Nordisk stock opened sharply higher, partially recovering some of Friday's heavy losses after disappointing data for its experimental weight-loss drug CagriSema prompted a selloff. U.S.